India & Astec LifeSciences
6 shared events · Importance 3 · Last updated Mar 31, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: India will benefit from increased access to advanced multi-cancer detection screening, potentially improving public health outcomes by enabling earlier diagnosis and treatment of various cancers.
Astec LifeSciences: Astec LifeSciences has partnered with Apollo Hospitals and Guardant Health to introduce the Shield Multi-Cancer Detection test in India, expanding its oncology diagnostics portfolio and market reach. Its shares rose following the announcement.
Jul 03, 2026 · 6 articles
Business
India: India is the home country of Cipla and several competing firms, and the deal reflects India's growing role in global biosimilar development.
Astec LifeSciences: Zydus is a competitor developing its own Keytruda biosimilar (FYB206) with Formycon AG, facing similar market opportunities.
Sep 03, 2026 · 6 articles
Regulatory
India: Home market of Biocon and several competing biosimilar makers; the approval enhances India's position in global biosimilar exports.
Astec LifeSciences: One of several Indian domestic players marketing a Pertuzumab biosimilar alternative in India, facing increased competition from Biocon's European expansion.
Sep 21, 2026 · 7 articles
Business
Astec LifeSciences: Astec LifeSciences is among the Indian pharmaceutical companies that have introduced generic semaglutide brands, contributing to the market shift.
Mar 30, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Astec LifeSciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard